Bentley Systems Bolsters Cesium with Reality Modeling Capabilities, Brings Geospatial Context to Infrastructure Engineering
15.10.2025 09:50:00 CEST | Business Wire | Press Release
(Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the availability of reality modeling services in Cesium, advancing its open platform for the built and natural environment. It also unveiled geospatial capabilities for project delivery and asset performance and a new immersive engagement application for infrastructure teams and stakeholders, all powered by Cesium.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015286327/en/
Bentley announced the availability of reality modeling services in Cesium, advancing its open platform for the built and natural environment. (Image courtesy of Bentley Systems)
Since acquiring Cesium a year ago, Bentley has made significant progress in integrating technologies from both companies, powering its own products and empowering developers to build applications that visualize infrastructure data in real time and in full geospatial context.
“Our vision for infrastructure engineering is built on openness,” said Patrick Cozzi, Bentley’s chief platform officer. “With the integration of iTwin and Cesium capabilities, we are creating the open platform for the built and natural environment—providing all the necessary data for infrastructure professionals to design, build, and operate in a real-world context.”
Adding reality modeling and AI-powered analysis to Cesium
Bentley has added reality modeling services from iTwin Capture to Cesium ion, creating a complete, automated pipeline from data capture through geospatial visualization. iTwin Capture creates engineering-grade reality models from imagery and applies AI-powered feature detection, while Cesium ion allows developers to create and host content in the cloud to power 3D geospatial applications.
With the new reality modeling capabilities, Cesium ion can create detailed 3D visualizations—reality meshes, point clouds, and Gaussian splats—directly from imagery, annotated by AI, ready to stream within applications using open standards. Creating an accurate, engineering-grade digital model of the existing built and natural environment and offering it as rich 3D geospatial context allows infrastructure professionals to make better informed decisions throughout the infrastructure lifecycle.
"Being able to generate photogrammetry, point clouds, and Gaussian splats as 3D Tiles from drone imagery, stream them seamlessly to the web, and analyze the point clouds is a major milestone,” said Osarodion Victory Igbinobaro, co-founder and CEO of AERO AI, a Cesium user. “This release brings end-to-end 3D reality modeling into one accessible, high-performance pipeline.”
The reality modeling capabilities in Cesium ion will be generally available before the end of 2025.
Enhancing project delivery and asset performance with geospatial context
Cesium capabilities are also enhancing Bentley’s product portfolio, bringing geospatial context to Bentley Open Applications and Bentley Infrastructure Cloud.
MicroStation 2025, the latest release of Bentley’s CAD software for infrastructure design, introduces support for 3D Tiles via Cesium. Engineers can now seamlessly integrate any 3D Tiles content, including Google Photorealistic 3D Tiles and their own high-fidelity reality data, directly into their design projects. This reduces the need to manually model existing conditions, accelerating project setup and allowing teams to focus on designing solutions. These same capabilities are coming to Bentley Open Applications built on MicroStation, for designing roads, railways, bridges, and more.
Cesium is also powering the geospatial experience in Bentley Infrastructure Cloud Connect, Bentley’s unified environment to connect data and people across the infrastructure lifecycle. With this geospatial context, also featuring Google Photorealistic 3D Tiles, users can navigate more intuitively across and within their projects and assets available in Bentley Infrastructure Cloud.
Introducing iTwin Engage
Bentley also announced iTwin Engage, which enables infrastructure teams and their stakeholders to engage immersively with digital twins of future and existing infrastructure assets.
Engineers often need to create immersive, photorealistic renderings to present their design work. Traditionally, this process is slow and inefficient, requiring specialized skills and resulting in static visuals that quickly become outdated as the design models evolve. With iTwin Engage, powered by Cesium and game engine technology, anyone can build impactful, narrative-driven content that brings projects and assets to life. Experiences are automatically generated, always current thanks to a live connection to the digital twin, and interactive—enabling not only design reviews, but also digital rehearsals for construction, immersive remote inspections, and more.
“The opportunity to present and communicate the project plan through iTwin Engage, in such an appealing manner, is fantastic,” said Simon Beards, principal planner, Laing O’Rourke, a participant in an early access program. “The greater the involvement the team has on the plan, the more likely there is a chance of success, as it supports a more collaborative way of engineering improvements.”
iTwin Engage will be in limited availability by the end of 2025.
# # #
About Bentley Systems
Around the world, infrastructure professionals rely on software from Bentley Systems to help them design, build, and operate better and more resilient infrastructure for transportation, water, energy, cities, and more. Founded in 1984 by engineers for engineers, Bentley is the partner of choice for engineering firms and owner-operators worldwide, with software that spans engineering disciplines, industry sectors, and all phases of the infrastructure lifecycle. Through our digital twin solutions, we help infrastructure professionals unlock the value of their data to transform project delivery and asset performance.
© 2025 Bentley Systems, Incorporated. Bentley, the Bentley logo, Cesium, Cesium ion, 3D Tiles, iTwin, Bentley Infrastructure Cloud, MicroStation, Bentley Open Applications, iTwin Capture, and iTwin Engage are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251015286327/en/
Contacts
For more information, contact:
Bentley Press: Chris Phillips, PR@news.bentley.com
Bentley Investors: Eric Boyer, IR@bentley.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom